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ABSTRACT 
Background: Intravenous administration is the route of choice for drug 
therapy in the immediate postoperative period. Propacetamol (ProAPAP), an 
injectable prodrug of paracetamol requiring reconstitution, has demonstrated 
efficacy in managing acute pain and fever. However, it has been associated with 
pain at the injection site. A stable, ready-to-use formulation of paracetamol solu- 
tion infused intravenously (IV-APAP) has been developed and might be associated 
with less pain at the injection site compared with ProAPAP. 
Objective: The objective of this study was to assess the tolerability and efficacy 
of a single dose of IV-APAP 1 g compared with those of a single dose of ProAPAP 2 g 
in patients with moderate to severe pain after minor gynecologic surgery. 
Methods: This single-dose, randomized, double-blind, active-controlled, 
2-parallel-group study was conducted at 23 hospitals and outpatient clinics in 
France. After minor gynecologic surgery, patients reporting moderate to severe 
pain were randomized to receive a single 15-minute infusion of IV-APAP 1 g or 
ProAPAP 2 g (bioequivalent doses). Tolerability was monitored using local and 
systemic adverse vent (AE) reporting, clinical examination including vital sign 
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measurement, and patients' ratings of acceptability of the infusion. Efficacy end 
points included pain intensity at 0, 1, 2, 4, and 6 hours; median time to rescue 
medication (defined as the time at which 50% of patients requested rescue medi- 
cation); and percentage of patients requesting rescue medication. Patients' sat- 
isfaction with the study drugs was assessed using patient's global evaluation 
(PGE) and the percentage of patients willing to receive the treatment again. 
Results: Of the 163 women who were randomized, 161 received the study 
medication. The IV-APAP group comprised 80 patients (mean [SD] age, 38.3 
[12.8] years [range, 18.0-69.0 years]; mean [SD] weight, 61.1 [11.0] kg [range, 
49.0-90.0 kg]), and the ProAPAP group comprised 81 patients (mean [SD] age, 
33.9 [12.0] years [range, 18.0-67.0 years]; mean [SD] weight, 61.6 [10.2] kg [range, 
42.0-95.5 kg]); the difference in mean age between the 2 groups was statistically 
significant (P < 0.05). The incidence of local treatment-emergent AEs (TEAEs) 
was significantly lower in the IV-APAP group compared with that in the ProAPAP 
group (7.5% vs 38.2%; P< 0.001). No between-group differences in the incidence 
of systemic TEAEs was found. All patients in the IV-APAP group found the infu- 
sion tolerable, compared with 95% of patients in the ProAPAP group. The median 
time to rescue medication was not evaluated because <50% of the patients in 
each group requested it. No significant differences in mean pain intensity score 
or percentage ofpatients requesting rescue medication were found between the 
2 groups at any time point. The percentages of patients in the IV-APAP and 
ProAPAP groups who rated the study medication as good or excellent on the 
PGE (83.6% vs 75.6%; P < 0.05) and who were willing to receive the same treat- 
ment again (96.0% vs 81.0%; P = 0.005) were significantly higher with IV-APAP 
compared with ProAPAP. 
Concluslon: In these patients with moderate to severe pain after minor 
gynecologic surgery, a single dose of IV-APAP was associated with better local 
tolerability, similar analgesic efficacy, and greater patient satisfaction com- 
pared with a single bioequivalent dose of ProAPAP. (Curr Ther Res Clin Exp. 
2005;66:294-306) Copyright © 2005 Excerpta Medica, Inc. 
Key words: paracetamol, propacetamol, intravenous, acetaminophen, post- 
surgical pain management, gynecologic surgery. 
INTRODUCTION 
Intravenous administration is the route of choice for drug therapy in the imme- 
diate postoperative period. However, because of its poor solubility, paracet- 
amol (acetaminophen), a commonly used analgesic agent, was not available 
as an injectable formulation until recently. Propacetamol (ProAPAP), an inject- 
able prodrug of paracetamol that requires reconstitution, has been available 
since 1985 and is used for managing acute pain and fever. In the blood, ProAPAP 
is rapidly cleaved by plasma esterases into paracetamol and an inactive pro- 
moiety (diethylglycine); 2 g of ProAPAP provides 1 g of paracetamol by the end 
of infusion. 
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A stable, ready-to-use formulation of intravenous paracetamol (IV-APAP) has 
been developed, allowing for IV administration f paracetamol itself. It is provided 
in a 100-mL vial containing 1g of paracetamol r a 50-mL vial containing 500 mg 
of paracetamol diluted in water for injection. IV-APAP does not require reconsti- 
tution and thus might decrease the risks for contamination a d dosage rror. 1 
The pH and osmolarity of ProAPAP (3.5 and 410 mOsm/L, respectively) are 
far from those of plasma (ranges, 7.3-7.4 and 275-295 mOsm/L, respectively). 
Thus, ProAPAP has been associated with pain at the injection site. 2 In contrast, 
the pH and osmolarity of IV-APAP (5.5 and 290 mOsm/L, respectively) are more 
similar to those of plasma, which might lead to less pain at the injection site 
compared with ProAPAP. 
In a pharmacokinetic study with a randomized, open-label, 3-period, cross- 
over design, Flouvat et al 3 compared the pharmacokinetic properties of 2 differ- 
ent doses of IV-APAP with those of ProAPAP in 24 healthy volunteers. Single 
doses of IV-APAP 0.5 g, IV-APAP 1 g, and ProAPAP 2 g were given, with a 1-week 
washout period between doses. After the administration of IV-APAP 0.5 and 
1.0 g, the pharmacokinetic properties of paracetamol were found to be linear. 
The 90% Cls for the Cma xand AUC0_ ~ ratios of IV-APAP to ProAPAP were within 
acceptable bioequivalence ranges, indicating that IV-APAP 1 g is bioequivalent 
to ProAPAP 2 g. Pain at the infusion site was found in 2% of patients receiving 
IV-APAP versus 20% receiving ProAPAP. Randomized clinical trials of IV-APAP in 
adults with postoperative pain after dental 4and orthopedic 5 surgery and chil- 
dren after hernia repair ~ have also shown improved local tolerability and simi- 
lar efficacy compared with ProAPAP. 
The objective of this study was to assess the tolerability and efficacy of a sin- 
gle dose of IV-APAP 1 g compared with those of a single dose of ProAPAP 2 g in 
patients with moderate to severe pain after minor gynecologic surgery. 
PATIENTS AND METHODS 
This single-dose, randomized, ouble-blind, active-controlled, 2-parallel-group study 
was conducted at 23 hospitals and outpatient clinics in France. It was conducted in
accordance with the Good Clinical Practice guidelines 7 and the Declaration of 
Helsinki and its amendments. 8 The protocol was approved by an independent ethics 
committee (Comit6 de Protection des Personnes de Paris Bichat-Claude Bernard, 
Paris, France). Patients were enrolled from March 2001 to February 2002. 
Inclusion and Exclusion Criteria 
Patients aged 18 to 70 years scheduled for elective minor gynecologic sur- 
gery to be performed using standardized general anesthesia and who were to 
receive postoperative care in a hospital or outpatient clinic for at least 6 hours 
after study drug administration were eligible for the study. Additional inclusion 
criteria were as follows: body weight 50 to 100 kg; American Society of 
Anesthesiologists 9 physical status P1 or P2 (healthy or mild systemic disease); 
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and ability to understand the study procedures, including the use of pain scales 
after training was given. Except for patients undergoing elective abortion, women 
of childbearing potential were to have been using oral, implanted, or injectable 
contraceptive hormones or mechanical contraceptive products and to have a 
negative urinary pregnancy test within 72 hours before study drug administra- 
tion. Eligible patients provided written informed consent o participate. 
Exclusion criteria included a history of known or suspected alcohol or drug 
abuse, psychiatric disease, or medical conditions that might invalidate par- 
ticipation in the trial; a history of complete nonresponse to paracetamol 
or NSAIDs when seeking pain relief; poor venous access; and participation 
in another clinical study within the 30 days before the study. Patients with 
any contraindication to the study drugs or any painful physical condition 
(other than postoperative pain) were also excluded. Patients were excluded if 
they had a known hypersensitivity to ProAPAP, paracetamol, phenacetin, 
anesthetics and related compounds, or the inactive ingredients in the study 
medications. 
Patients who had used paracetamol r any NSAID or analgesic within 12 hours 
before study drug administration, or any concomitant treatment that might con- 
found the quantification of analgesia, and patients treated with corticosteroids 
within 7 days before surgery were ineligible. Patients were also excluded if they 
were treated with any microsomal enzyme inducer (eg, barbiturates, isoniazid, 
anticonvulsants) before the study. Finally, patients with cysteinic lithiasis, im- 
paired hepatic function, advanced renal dysfunction, or chronic malnutrition 
were excluded from the study. 
Anesthesia and Study Drug Administration 
During the screening visit, which was scheduled within 21 days before sur- 
gery, informed consent and medical history were obtained by the investiga- 
tor; physical examination and laboratory testing (renal and hepatic function 
tests) were performed. Training in the use of pain scales was provided to 
patients. 
On the day of surgery, patients received standardized general anesthesia 
(premedication using hydroxyzine or midazolam; induction with propofol, fen- 
tanyl, or alfentanil; intubation with curare as needed; and maintenance with 
propofol or halogenated gas as required), without any epidural or intrathecal 
opioids or local anesthetics for postoperative pain control. 
After surgery, on recovery of consciousness, patients were asked by the 
study observer to rate the intensity of their pain using a 4-point verbal scale 
(0 = none; 1 = mild; 2 = moderate; and 3 = severe). Patients who rated their pain 
intensity as moderate to severe were randomly assigned, in a 1:1 ratio accord- 
ing to a computer-generated list of random numbers, to 1 of 2 treatment groups: 
IV-APAP 1 g or ProAPAP 2 g. 
The study medications were prepared by an unblinded hospital pharmacist or 
nurse who was not involved in the data collection. The study medications were 
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administered asa 100-mL solution infused over 15 minutes through acannula dedi- 
cated to the study medications. To properly assess the tolerability of the medica- 
tion at the infusion site, no other drugs were administered through the cannula. 
In case of insufficient pain relief with the study medications, patients were 
allowed to receive the usual rescue medication used in each center. Patients 
were encouraged to wait for at least 1 hour after the start of the infusion before 
requesting rescue medication. 
Tolerability Assessments 
Adverse events (AEs) were monitored throughout the 6-hour study period 
using patient interview and spontaneous reporting. The severity of systemic 
AEs was assessed by a blinded investigator. In cases of spontaneous reporting 
of pain at the infusion site, local pain intensity, as assessed by the patient using 
a 4-point verbal scale (0 = none; 1 = mild; 2 = moderate; and 3 = severe), was 
recorded. Vital signs, including blood pressure, heart rate, and respiratory rate, 
were measured at 2 and 6 hours after dosing. Blood pressure was measured 
with the patient in the supine position, using a mercury sphygmomanometer or 
an automated blood pressure cuff. 
Immediately after study drug administration, patients were asked to evaluate 
the acceptability of the infusion by answering the question, "Was the infusion 
tolerable for you?" 
Biochemical parameters were not assessed in this study because the biolog- 
ical safety of the study drugs has been shown previously. 2,4,5 
Efficacy Measurements 
For the efficacy assessment, patients were asked to rate their pain inten- 
sity, both on the 4-point verbal scale and on a 100-mm visual analog scale 
(VAS) (0 = no pain to 100 = worst possible pain). Pain intensity was assessed 
at 0 (immediately before infusion; baseline), 1, 2, 4, and 6 hours after dosing. 
Time to request for rescue medication was recorded. Patients' satisfaction 
with the study drug was assessed using a patient's global evaluation (PGE) 
scale (0 = poor; 1 = fair; 2 = good; and 3 = excellent) and their willingness 
to receive the same treatment again. This assessment was performed at 
6 hours after dosing, time rescue medication was requested, or time of study 
withdrawal. 
Statistical Analysis 
It was calculated that a sample size of 80 patients per group was required to 
detect a 50% reduction in the proportion of patients experiencing local AEs for 
IV-APAP versus ProAPAP, with 80% power and u = 0.05, based on an anticipated 
rate of 40% to 50% of patients in the ProAPAP group and 20% to 25% in the 
IV-APAP group experiencing local AEs. 
All analyses were performed in the intent-to-treat (ITT) population (patients 
who received the study treatment). 
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The incidence of AEs was analyzed using the •2 test or the Fisher exact test, 
and descriptive statistics were used to analyze the changes in vital signs. 
Mean pain intensity scores were calculated and compared using analysis of 
covariance, adjusting for baseline pain intensity score. Median time to rescue med- 
ication, defined as the time at which 50% of the patients had requested it, was 
treated as a survival-type response and was analyzed using the stratified Gehan- 
Wilcoxon test, 1° with baseline pain intensity (verbal scale) as the stratum variable. 
In comparing the 2 treatment groups, the Cochran-Mantel-Haenszel test stratified 
by baseline pain intensity (verbal scale) was used for analysis of the need for res- 
cue medication, PGE, and patients' willingness to receive the treatment again. 
Statistical analyses were performed using SAS version 8.2 (SAS Institute Inc., 
Cary, North Carolina). P < 0.05 was considered statistically significant. 
RESULTS 
Study Population 
A total of 163 women were enrolled, and 161 received the single infusion of 
study medication. Two patients did not receive study medication (1 did not 
comply with the study protocol, and 1 discontinued). All 161 patients, including 
2 patients (1 in each group) who did not meet eligibility criteria (mild pain 
instead of moderate or severe pain) but were inadvertently included in the 
study, were included in the ITT population and analyses of demographic char- 
acteristics, tolerability, and efficacy. 
The IV-APAP group comprised 80 patients (mean [SD] age, 38.3 [12.8] years 
[range, 18.0-69.0 years]; mean [SD] weight, 61.1 [11.0] kg [range, 49.0-90.0 kg]), 
and the ProAPAP group comprised 81 patients (mean [SD] age, 33.9 [12.0] years 
[range, 18.0-67.0 years]; mean [SD] weight, 61.6 [10.2] kg [range, 42.0-95.5 kg]); 
the difference in mean age between the 2 groups was statistically significant 
(P < 0.05). Mean baseline pain intensity scores were statistically similar between 
the 2 treatment groups (Table I). 
Six patients received the entire infusion of study drug but did not complete 
the trial (IV-APAP: 1 patient due to noncompliance with trial instructions, and 
2 patients due to AEs [both, postoperative uterine hemorrhage]; ProAPAP: 1 pa- 
tient due to withdrawal of consent, and 2 patients due to AEs [1 patient each, 
postoperative uterine bleeding and uterine pain]). 
Tolerability 
AEs were reported by significantly fewer patients in the IV-APAP group com- 
pared with the ProAPAP group (14 [17.5%] vs 43 [53.1%]; P < 0.001). The per- 
centage of patients who reported AEs considered related to the study medica- 
tion was significantly lower in the IV-APAP group compared with the ProAPAP 
group (5 [6.3%] vs 35 [43.2%]; P < 0.001). 
Local treatment-emergent AEs (TEAEs) (pain and reaction at the injection 
site) occurred in a significantly lower number of patients in the IV-APAP group 
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(6 [7.5%] patients, all with pain) compared with the ProAPAP group (31 [38.3%] 
patients, 27 with pain and 4 with reaction) (P < 0.001) (Table II). These local 
TEAEs were considered treatment related in 5 of 6 patients in the IV-APAP group 
and in all 31 patients in the ProAPAP group. In most patients, local TEAEs were 
mild (IV-APAP, 5 [83.3%] patients; ProAPAP, 16 [51.6%] patients). Local TEAEs 
were reported as severe by 2 (6.5%) ProAPAP-treated patients. One (1.2%) pa- 
tient in the ProAPAP group discontinued treatment 10 minutes after the start of 
the 15-minute study drug infusion due to pain at the infusion site. The residual 
volume of the infused medication was 50 mL (1 g ProAPAP). 
Table I. Baseline demographic and clinical characteristics of the 
study patients (N = 161). 
IV-APAP ProAPAP 
Characteristic (n = 80) (n = 81) 
Age, y 
Mean (SD) 38.3 (1 2.8) 33.9 (1 2.0)* 
Median 38.0 31.0 
Range 1 8.0-69.0 1 8.0-67.0 
Weight, kg 
Mean (SD) 61.1 (11.0) 61.6 (1 0.2) 
Median 57 60 
Range 49.0-90.0 42.0-95.5 
Surgery type, no. (%) 
Hysteroscopy 28 (35.0) 23 (28.4) 
Elective abortion 19 (23.8) 25 (30.9) 
Celioscopy 10 (1 2.5) 12 (1 4.8) 
Curettage 10 (1 2.5) 7 (8.6) 
Conization 6 (7.5) 7 (8.6) 
Other 3 (3.8) 3 (3.7) 
Aspiration 2 (2.5) 1 (1.2) 
Hysterectomy 1 (1.3) 2 (2.5) 
Laser treatment for condyloma 1 (1.3) 1 (1.2) 
Pain intensity at the surgical site 
Verbal scale, no. (o/6) 
Mild 7 (8.8) 4 (4.9) 
Moderate 68 (85.0) 67 (82.7) 
Severe 5 (6.3) 10 (12.3) 
VAS score, t mean (SD), mm 37.7 (19.4) 41.1 (20.5) 
IV-APAP = injectable paracetamol; ProAPAP = propacetamol; VAS = visual analog 
scale. 
*P < 0.05 versus IV-APAP. 
tScale: 0 = no pain to 100 = worst possible pain. 
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Table II. Incidence of treatment-emergent adverse events (TEAEs) 
reported by >5% of patients (N = 161). Values are pre- 
sented as no. (%) of patients unless otherwise specified. 
IV-APAP ProAPAP 
TEAE (n = 80) (n = 81) 
Local 
Pain 6 (7.5) 27 (33.3)* 
Reaction 0 4 (4.9) 
Total local TEAEs, no. 6 31 
Total severe local TEAEs, no. 0 2 
Total patients with ~1 local TEAE 6 (7.5) 31 (38.3) t 
System ic 
Nausea 3 (33.3) 5 (26.3) 
Vomiting 3 (33.3) 5 (26.3) 
Uterine hemorrhage 2 (22.2) 1 (5.3) 
Migraine 1 (11.1 ) 0 
Abdominal pain 0 3 (15.8) 
Back pain 0 1 (5.3) 
Other gastrointestinal disorders ~ 0 1 (5.3) 
Uterine atony 0 1 (5.3) 
Uterine disorders 0 1 (5.3) 
Pyrexia 0 1 (5.3) 
Total systemic TEAEs, no. 9 19 
Total severe systemic TEAEs, no. 0 3 
Total patients with :-1 systemic TEAE 8 (10.0) 15 (18.5) 
Total TEAEs 15 50 
Total patients with :-1 TEAE 14 (1 7.5) 43 (53.1) t 
IV-APAP = injectable paracetamol; ProAPAP = propacetamol. 
*One patient withdrew clue to this TEAE. 
tp < 0.001 versus IV-APAP. 
*Includes intestinal transit disorders. 
There were no between-group differences in the incidence of systemic 
TEAEs, with 8 (10.0%) patients in the IV-APAP group having reported at least 
1 systemic TEAE compared with 15 (18.5%) patients in the ProAPAP group. 
Systemic TEAEs were reported as severe by 3 (15.8%) patients treated with 
ProAPAP (uterine hemorrhage, abdominal pain, vomiting). None of the patients 
discontinued the study due to a systemic TEAE. No significant changes in vital 
signs were observed. 
All patients in the IV-APAP group found the infusion acceptable compared 
with 77 (95.0%) patients in the ProAPAP group. 
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Eff icacy 
There were no significant differences in mean scores on the verbal scale 
(Figure 1) or VAS (Figure 2) between the 2 treatment groups at any time point. At 
___1 hour after dosing, the mean VAS scores were <30 mm (considered the threshold 
for clinically significant pain). 
No statistically significant differences in the numbers of patients requesting 
rescue medication were found between the 2 groups at any time during the 
study (at study end, 20 [25.0%] vs 27 [33.3%]) (Figure 3). The median time to 
rescue medication was not evaluated because <50% of the patients in either 
group requested rescue medication. 
A significantly higher number of patients in the IV-APAP group assessed the 
treatment they received as good or excellent on the PGE compared with that in the 
ProAPAP group (66 [83.6%] vs 59 [75.6%]; P < 0.05), with the remainder of patients 
assessing the treatments a fair or poor. Similarly, a significantly higher percentage 
of patients in the IV-APAP group were willing to receive the same treatment again 
compared with that in the ProAPAP group (76 [96.0%] vs 64 [81.0%]; P = 0.005). 
DISCUSSION 
In this comparison of the tolerability and efficacy of IV-APAP and ProAPAP, 
ProAPAP was chosen as the comparator because it was the only injectable formu- 
Figure 1. 
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Time After Study Drug Administration (h) 
Percentages of patients who rated pain as moderate to severe after receiv- 
ing a single dose of injectable paracetamol (IV-APAP) or propacetamol 
(ProAPAP) for postsurgical pain management. No significant between- 
group differences were found. 
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Figure 2. 
Time After Study Drug Administration (h) 
Mean pain intensity scores, as measured on a 100-mm visual analog scale 
(0 = no pain to 100 = worst possible pain), in patients receiving a single dose 
of injectable paracetamol (IV-APAP) or propacetamol (ProAPAP) for postsurgi- 
cal pain management. No significant between-group differences were found. 
Figure 3. 
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Time After Study Drug Administration (h) 
Percentages of patients who did not request rescue medication after receiv- 
ing a single dose of injectable paracetamol (IV-APAP) or propacetamol 
(ProAPAP) for postsurgical pain management. Because <50% of patients 
requested rescue medication, the median time to rescue medication use 
was not assessable. No significant between-group differences were found. 
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lation of paracetamol commercially available in Europe at the time of the study. 
The amount of 2 g of ProAPAP was chosen because it has been shown to be bio- 
equivalent to 1 g of paracetamol. 3 No placebo group was included because the main 
objective of the study was the tolerability assessment, and both ProAPAP and 
IV-APAP have shown significant analgesic efficacy compared with placebo. 2,4,5,11,12 
We found that IV-APAP was well tolerated in the study population. As reported 
in previous clinical trials, 3-5 a significantly smaller percentage of patients expe- 
rienced local TEAEs in this group compared with the ProAPAP group (7.5% vs 
38.3%; P < 0.001). This difference was likely due to the pH and osmolarity of 
IV-APAP, which are closer to those of plasma than are the pH and osmolarity of 
ProAPAP. As reported previously, 2 pain at the infusion site was the most com- 
mon TEAE associated with ProAPAP. 
The analgesic efficacy of IV-APAP, as measured by pain intensity score, was 
similar to that of ProAPAP, supporting (in this first study comparing these 
drugs in the treatment of postoperative pain management after minor visceral 
surgery in adults) previous studies that have shown the analgesic efficacy of 
IV-APAP after dental 4and orthopedic surgery. 5Regarding the magnitude of the 
analgesic effect, at >1 hour after dosing, the mean VAS scores were <30 mm--  
the value commonly considered to be the threshold for clinically significant 
pain. 13 
In addition to better local tolerability and comparable analgesic efficacy, 
the potential advantages of IV-APAP over ProAPAP include decreased risks for 
contamination and dosage error, as well as reduced nurse's time and need for 
ancillary products, because reconstitution is not required. Finally, occupational 
contact dermatitis, a risk for health care providers who handle ProAPAP, is un- 
likely to occur with IV-APAP. 1 
The general tolerability of both medications was good, supporting the good 
general safety profile of paracetamol, which has a historically low incidence of 
AEs (with hepatotoxicity and hepatic failure being associated only with higher- 
than-recommended doses)and untoward rug-drug interactions. 14Paracetamol 
has not been found to induce nausea, vomiting, or respiratory depression 
(which are commonly induced by opioids), making it useful in the postopera- 
tive setting. Paracetamol also has not been found to be associated with delete- 
rious gastrointestinal effects; inhibition of platelet function; increased risk for 
perioperative bleeding; nephrotoxicity observed with NSAIDs15-18; salt or water 
retention or hypertension described with selective cyclooxygenase-2 inhib- 
itors. 19 Furthermore, paracetamol has not been shown to interact with drugs 
commonly used in the postoperative s tting. 2° 
After treatment with IV-APAP, patients' satisfaction with treatment was con- 
sidered better with IV-APAP, as suggested by the PGEs of the study drug and 
their willingness to receive the same treatment again. Therefore, the results of 
the present study, which showed the better local tolerability and similar anal- 
gesic efficacy of IV-APAP compared with ProAPAP, suggest hat IV-APAP is a 
viable option in postsurgical pain management. 
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CONCLUSION 
In these patients with moderate to severe pain after minor gynecologic surgery, 
a single dose of IV-APAP was associated with better  local tolerability, similar 
efficacy, and greater patient satisfaction compared with a single bioequivalent 
dose of ProAPAP. 
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